Select region:

Clinical trials located in

Bristol

Bristol city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Bristol, a vibrant city in the United Kingdom, boasts a rich maritime history. It is the birthplace of the famous 19th-century engineer Isambard Kingdom Brunel, who designed the iconic Clifton Suspension Bridge. The city is also known for its thriving street art scene, notably being home to the elusive artist Banksy. Bristol’s cultural landscape includes the historic Old Vic Theatre, the oldest continuously working theatre in the English-speaking world. Additionally, it has a strong environmental focus, being named Europe’s Green Capital in 2015.

  • CT-EU-00112464

    Testing setmelanotide for weight loss in genetic obesity

    This study is a research project looking into the effectiveness of a medication called setmelanotide for people who are dealing with obesity due to specific genetic variations. This medication is given under the skin. The study is designed to see if setmelanotide can help people lose weight compared to a placebo, which don’t contain any active medication.

    The study focuses on individuals who have one of several gene variants in the Melanocortin-4 Receptor pathway. These variants include changes in the POMC or PCSK1 genes, the LEPR gene, the SRC1 gene, or the SH2B1 gene. Depending on which gene variant a participant has, they will be placed into one of four sub-studies.

    The main goal of this clinical trial is to measure how much weight participants lose while taking setmelanotide over a period of 52 weeks. This will be compared to the weight loss of participants who receive the placebo. The study is carefully controlled and blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo until the study is completed.

    This trial is an important step in understanding how setmelanotide can help people with obesity linked to specific genetic factors, offering hope for a targeted treatment option.

    FranceGermanyGreeceNetherlandsSpainUnited Kingdom
  • Sparsentan Treatment Study for Children with Kidney Diseases

    We are excited to introduce a clinical trial focused on the study of Sparsentan treatment in children and adolescents with certain types of kidney diseases that lead to protein loss in urine, known as proteinuric glomerular diseases. This includes conditions like Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), IgA Vasculitis (IgAV), and Alport Syndrome (AS).

    The main goal of this study is to understand how safe, effective, and tolerable Sparsentan is when given as an oral suspension or tablet. We are particularly interested in seeing how this treatment can change the levels of protein in the urine over a period of 108 weeks.

    This study is designed as a Phase 2, Open-Label, Single-Arm trial, meaning all participants will receive the treatment, and there will not be a comparison group receiving a placebo. We are looking to enroll approximately 67 pediatric subjects, aged 1 year to less than 18 years, who have been diagnosed with one of the specified conditions. The study is divided into three populations based on the specific disease and age groups, with different dosages of Sparsentan being tested across these groups.

    The safety of the participants will be closely monitored throughout the study, with a special focus on any treatment-emergent adverse events, serious adverse events, and any adverse events that may lead to discontinuation of the treatment. Additionally, we will measure the change in the urine protein/creatinine ratio (UP/C) from the start of the study to week 108 to assess the effectiveness of Sparsentan in reducing proteinuria.

    This study represents an important step towards finding a potentially effective treatment for children and adolescents suffering from these challenging kidney diseases. If you or your child are dealing with one of these conditions and are interested in participating, we encourage you to consider this unique opportunity.

    GermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Clinical Study on Growth and Health in Children with Achondroplasia

    This is a long-term, multi-center, observational study for children aged 2.5 to <17 years who have been diagnosed with achondroplasia. The main objective of the study is to evaluate various aspects of the condition, including growth, medical complications related to achondroplasia, health-related quality of life, body pain, functional abilities, cognitive functions, and treatments received by the participants. The study will monitor changes in height Z score and upper to lower body segment ratio over a period of up to 2 years. No study medication will be administered to the participants during this observational study.

    FranceGermanyItalyNorwaySpainUnited Kingdom
  • CT-EU-00091315

    Testing infigratinib in children aged 3 to 11 years with achondroplasia

    This study focuses on evaluating the medication Infigratinib in young children aged 3 to 11 diagnosed with Achondroplasia who previously participated in the PROPEL study for at least 6 months. The primary objectives of this study are to assess the safety profile of Infigratinib in this specific age group, evaluate the children’s tolerance to potential side effects, and investigate the therapeutic efficacy of the medication for treating Achondroplasia. During the study, doses of Infigratinib will be incrementally increased to determine the optimal and most effective dosage for the participants.

  • Ceralasertib & durvalumab vs docetaxel in advanced lung cancer study

    This is an open-label study titled LATIFY, which means everyone will know the type of treatment they are receiving. The study team is looking into a specific type of lung cancer, called Non-Small Cell Lung Cancer (NSCLC) which did not get better after previous treatments. Two treatments will be tested, a new combination of ceralasertib plus durvalumab, compared to a commonly used treatment, docetaxel. Doctors will track participants’ health over time to see which treatment helps people live longer. Understanding the results will help doctors responsibly give the best treatment for patients with this type of lung cancer.

    BelgiumFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    AustriaBelgiumFranceGermanyItalyNetherlandsNorwayPolandPortugalSlovakiaSpainUnited Kingdom
  • Fianlimab and cemiplimab: a new treatment for melanoma patients

    The study is underway to determine the most effective treatments in preventing the recurrence of melanoma, a form of skin cancer, following surgical removal. The medicines being tested are Fianlimab and Cemiplimab together or another medicine called Pembrolizumab. The trial aims to assess whether the Fianlimab and Cemiplimab combination outperforms Pembrolizumab in preventing cancer recurrence and if patients administered Fianlimab and Cemiplimab live longer. Additionally, the study seeks insights into the impact of treatments on patients’ quality of life, the occurrence of minor or major side effects, and how these drugs behave inside the patient’s body.

    BelgiumCzechiaFranceGermanyGreeceItalyPolandRomaniaSpainUnited Kingdom
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryNetherlandsNorwayPolandSwedenUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Long-term study on donidalorsen in hereditary angioedema

    This is a research assessing the long-term safety and effectiveness of donidalorsen in the prophylactic treatment of hereditary angioedema (HAE-1 and HAE-2). The study includes two groups of participants: 1) individuals transitioning from another study with donidalorsen, and 2) new participants not transitioning from another donidalorsen study, who were previously on prophylactic therapy with lanadelumab, berotralstat, or a C1-esterase inhibitor (C1-INH). The duration of participation in the study is 70 or 76 weeks.

    BelgiumBulgariaFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Studying camlipixant for chronic cough treatment

    This study involves a year-long study of a drug known as Camlipixant (BLU-5937). The aim is to evaluate its potential effectiveness in treating persistent cough in adults who have not found relief with alternative treatments. The methodology involves giving Camlipixant (BLU-5937) to some participants and a placebo to others. The allocation of the real drug or placebo is not disclosed to all study participants. After 12 weeks of taking Camlipixant, your daily cough frequency will be assessed. The purpose of this evaluation is to determine whether it has a noticeable effect. Additionally, participants will be asked to self-assess the severity of their cough on a scale. Finally, participants will be asked to complete a survey detailing the impact of cough on everyday life, emotional well-being and interpersonal relationships.

    BelgiumFranceHungaryNetherlandsPolandSpainUnited Kingdom
  • Testing ustekinumab treatment for severe ulcerative colitis

    This clinical trial is focused on understanding the safety and effectiveness of a medication named Ustekinumab in children and adolescents who are experiencing moderate to severe Ulcerative Colitis (UC), a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract. The study administers Ustekinumab initially through an IV (intravenous infusion) and then as a subcutaneous injection. The main aims are to determine whether Ustekinumab can help these young patients achieve clinical remission, meaning their UC symptoms are reduced or completely go away, and to monitor how the drug behaves in their bodies. Throughout the trial, the health and safety of the participants are closely monitored.

    BelgiumGermanyHungaryPolandUnited Kingdom
  • Fenfluramine Hydrochloride study for seizure control in cyclin-dependent kinase like-5 (CDKL5)

    This is studying a new substance called Fenfluramine Hydrochloride (ZX008) in children and adults experiencing seizures with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD). The research has two parts. In the first part, lasting 20 weeks, some participants receive the new drug, while others receive a placebo (inactive substance). This part aims to determine if ZX008 is effective and safe. The second part lasts 54 weeks and is open-label, meaning everyone is aware they are receiving the active drug. It helps assess long-term effects. If participants complete the first part, they can enroll in the second part, including an open-label treatment period (52 weeks) and a taper period (2 weeks).

    AustriaBelgiumGermanyNetherlandsPortugalSpainUnited Kingdom
  • Testing tovorafenib in treating low-grade glioma

    This study is a comparative test between tovorafenib (DAY101) and the standard chemotherapy typically administered to children with low-grade glioma, a specific type of brain tumor. The experiment involves approximately 400 children who have not yet received treatment for their glioma. The participants will be divided into two groups. In the first group, children will be administered DAY101, taking it every 28 days until one of the following events occurs: they no longer benefit from the treatment, it becomes unsafe, they choose to leave the experiment, or the experiment concludes. In the second group, children will receive one of three common chemotherapy drugs selected by their doctor, and they will continue with the treatment until similar circumstances prompt a change, as outlined for the first group. If the tumor continues to grow while on DAY101 but the treatment remains beneficial, participants can continue taking it. Likewise, if the tumor continues to grow while on chemotherapy, participants can stop and transition to DAY101.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwaySloveniaSpainSwedenUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Researching vamikibart for uveitic macular edema treatments

    The study investigates Vamikibart, a new drug for adults with uveitic macular edema, a condition causing swelling in the eye and vision problems. It tests how well Vamikibart, given as eye injections, can improve vision compared to a sham procedure. The goal is to find a safe, effective treatment for this eye condition, helping people see better and manage their symptoms.

    AustriaItalyNetherlandsPolandPortugalUnited Kingdom
  • Testing ranibizumab for neovascular age-related macular degeneration

    This study, called Velodrome, is looking into a new treatment method for a condition affecting the eyes called ‘Neovascular Age-Related Macular Degeneration’. The treatment uses a technique called the Port Delivery System, along with a drug called ranibizumab. The aim of the study is to see how safe and effective this treatment is over a period of 36 weeks, compared to a period of 24 weeks. This study is important because it might mean people with this condition might have to have fewer treatments, and potentially see better.

    AustriaBelgiumFranceGermanyItalySpainUnited Kingdom
  • Study on Tolebrutinib’s ability to delay disability progression in multiple sclerosis

    This is a study that involves a specific type of multiple sclerosis (MS) called primary progressive multiple sclerosis (PPMS). In this study, a drug called SAR442168, also known as Tolebrutinib, will be tested against a placebo. The main purpose of the study is to see if this drug can slow down the progression of disability in PPMS. The researchers will also look at the drug’s effect on clinical markers, brain images (MRI), thinking abilities, physical function, and quality of life. They will also consider the safety and tolerability of this drug. How long each person will take the drug can vary, but it will be somewhere between 12 and 60 months.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainSwedenUnited Kingdom

See more clinical trials in other cities in United Kingdom:

.